CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 18 enrolled
Drug / intervention
IGIV3I Grifolsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00699140
NCT00699140Phase 3Completed
CompareCT.gov

Clinical Trial to Evaluate the Efficacy and the Safety of IGIV3I Grifols 10% (Human Intravenous Immunoglobulin) in Patients Diagnosed With Immune Thrombocytopenic Purpura

Instituto Grifols, S.A.·interventional·Posted Jun 17, 2008·Updated Feb 8, 2016

In Brief

A Phase 3 clinical trial evaluating IGIV3I Grifols for Immune (Idiopathic) Thrombocytopenic Purpura. Completed, enrolled 18 participants across 7 sites in 3 countries.

Detailed Summary

The purpose of this study is to determine whether IGIV3I Grifols 10% is effective in the treatment of immune thrombocytopenic purpura.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmune (Idiopathic) Thrombocytopenic Purpura
CountriesRussia, Spain, United Kingdom
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 17, 2008
Enrollment StartFeb 1, 2008
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 18.0 years ago

Interventions

IGIV3I Grifolsbiological

Immune Globulin Intravenous (Human)